NCT04056442View on ClinicalTrials.gov

A Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 7, 2019

Primary Completion Date

November 7, 2022

Study Completion Date

November 7, 2022

Conditions
Steroid Dependent Crohn's Disease
Interventions
DRUG

Cannabidiol , synthetic form

Cannabidiol ( synthetic form)

DRUG

Placebo

Olive Oil Solution, 5%

Trial Locations (3)

Unknown

Soroka Medical Center, Beersheba

Meir Medical Center, Kfar Saba

Shamir Medical Center, Tzrifin

All Listed Sponsors
lead

Stero Biotechs Ltd.

INDUSTRY

NCT04056442 - A Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients | Biotech Hunter | Biotech Hunter